IRadimed Corporation (IRMD) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
39.29
↑+21% vs avg
5yr avg: 32.48
30Y Low10.3·High92.1
P/FCF
↑
68.21
+6% vs avg
5yr avg: 64.49
30Y Low16.9·High110.7
P/B Ratio
↑
12.46
↑+46% vs avg
5yr avg: 8.54
30Y Low4.2·High13.2
ROE
↑
24.8%
↓+19% vs avg
5yr avg: 20.9%
30Y Low2%·High45%
Debt/EBITDA
↓
N/A
—
5yr avg: 0.12
30Y Low0.0·High4.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IRMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
IRadimed Corporation trades at 52.4x earnings, 20% above its 5-year average of 43.5x, sitting at the 70th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a premium of 137%. On a free-cash-flow basis, the stock trades at 68.2x P/FCF, 6% above the 5-year average of 64.5x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.3B | $703M | $604M | $357M | $582M | $284M | $287M | $296M | $178M | $133M |
| Enterprise Value | $1.1B | $1.2B | $651M | $556M | $302M | $522M | $236M | $246M | $268M | $159M | $115M |
| P/E Ratio → | 52.39 | 55.59 | 36.67 | 35.16 | 27.74 | 62.45 | 207.27 | 29.97 | 47.04 | 378.75 | 18.50 |
| P/S Ratio | 13.98 | 14.92 | 9.60 | 9.21 | 6.71 | 13.91 | 8.94 | 7.45 | 9.73 | 7.69 | 4.10 |
| P/B Ratio | 12.46 | 13.22 | 8.10 | 8.46 | 4.85 | 8.06 | 4.62 | 5.17 | 7.06 | 5.39 | 4.17 |
| P/FCF | 68.21 | 72.78 | 39.90 | 110.66 | 43.77 | 55.33 | 54.75 | 29.45 | 41.65 | 68.53 | 16.88 |
| P/OCF | 46.98 | 50.12 | 27.44 | 44.85 | 35.60 | 51.68 | 48.76 | 28.05 | 40.16 | 51.98 | 14.15 |
P/E links to full P/E history page with 30-year chart
IRMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
IRadimed Corporation's enterprise value stands at 39.3x EBITDA, 21% above its 5-year average of 32.5x. The Healthcare sector median is 14.2x, placing the stock at a 177% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.31 | 8.89 | 8.48 | 5.66 | 12.49 | 7.45 | 6.40 | 8.81 | 6.90 | 3.55 |
| EV / EBITDA | 39.29 | 42.04 | 28.58 | 26.74 | 18.51 | 46.53 | 405.47 | 24.92 | 40.86 | 92.10 | 10.33 |
| EV / EBIT | 42.87 | 45.87 | 29.64 | 27.76 | 19.31 | 53.20 | — | 28.51 | 43.27 | 114.12 | 10.53 |
| EV / FCF | — | 69.80 | 36.95 | 101.91 | 36.94 | 49.67 | 45.61 | 25.29 | 37.71 | 61.50 | 14.64 |
IRMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
IRadimed Corporation earns an operating margin of 31.2%. ROE of 24.8% indicates solid capital efficiency. ROIC of 50.2% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.7% | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | 74.3% | 77.1% | 76.3% | 75.9% | 81.1% |
| Operating Margin | 31.2% | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | -2.4% | 22.5% | 19.7% | 5.6% | 33.6% |
| Net Profit Margin | 26.8% | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% | 2.2% | 22.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 24.8% | 24.8% | 24.3% | 23.7% | 17.6% | 14.0% | 2.3% | 19.8% | 16.8% | 1.5% | 22.6% |
| ROA | 21.7% | 21.7% | 20.2% | 19.4% | 15.2% | 12.1% | 2.0% | 16.7% | 14.4% | 1.3% | 19.9% |
| ROIC | 50.2% | 50.2% | 56.4% | 72.2% | 76.7% | 55.2% | -3.9% | 44.9% | 31.4% | 6.7% | 61.3% |
| ROCE | 27.8% | 27.8% | 26.5% | 26.2% | 20.4% | 13.8% | -1.2% | 16.5% | 15.3% | 3.8% | 33.2% |
IRMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $51M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.00 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | 0.01 | 0.10 | 0.14 | 0.22 | 4.66 | 0.30 | — | — | — |
| Net Debt / Equity | — | -0.54 | -0.60 | -0.67 | -0.76 | -0.82 | -0.77 | -0.73 | -0.67 | -0.55 | -0.56 |
| Net Debt / EBITDA | -1.79 | -1.79 | -2.29 | -2.29 | -3.42 | -5.30 | -81.26 | -4.10 | -4.27 | -10.52 | -1.59 |
| Debt / FCF | — | -2.98 | -2.96 | -8.74 | -6.83 | -5.66 | -9.14 | -4.16 | -3.94 | -7.03 | -2.25 |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($51M) exceeds total debt ($0)
IRMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
IRadimed Corporation's current ratio of 7.98x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 6.84x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 4.65x to 7.98x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.98 | 7.98 | 8.84 | 4.65 | 9.06 | 11.18 | 12.96 | 10.06 | 9.50 | 8.61 | 9.33 |
| Quick Ratio | 6.84 | 6.84 | 7.62 | 3.87 | 8.43 | 10.54 | 12.16 | 9.44 | 8.63 | 7.58 | 8.27 |
| Cash Ratio | 5.03 | 5.03 | 6.14 | 3.05 | 6.78 | 9.16 | 10.57 | 7.89 | 7.33 | 6.46 | 7.01 |
| Asset Turnover | — | 0.77 | 0.74 | 0.71 | 0.62 | 0.50 | 0.45 | 0.58 | 0.63 | 0.59 | 0.87 |
| Inventory Turnover | 1.68 | 1.68 | 1.62 | 1.20 | 2.24 | 2.27 | 2.07 | 2.42 | 1.78 | 1.32 | 1.58 |
| Days Sales Outstanding | — | 59.52 | 52.61 | 68.06 | 90.90 | 44.84 | 52.65 | 69.11 | 50.48 | 59.76 | 42.41 |
IRMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
IRadimed Corporation returns 1.3% to shareholders annually primarily through dividends. A payout ratio of 66.9% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 1.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.3% | 1.2% | 1.9% | 2.2% | 3.5% | — | — | — | — | — | — |
| Payout Ratio | 66.9% | 66.9% | 71.1% | 76.9% | 97.9% | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 1.8% | 2.7% | 2.8% | 3.6% | 1.6% | 0.5% | 3.3% | 2.1% | 0.3% | 5.4% |
| FCF Yield | 1.5% | 1.4% | 2.5% | 0.9% | 2.3% | 1.8% | 1.8% | 3.4% | 2.4% | 1.5% | 5.9% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 1.0% | 7.5% |
| Total Shareholder Yield | 1.3% | 1.2% | 1.9% | 2.2% | 3.5% | 0.0% | 0.0% | 0.0% | 0.1% | 1.0% | 7.5% |
| Shares Outstanding | — | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $12M | $12M |
Peer Comparison
Compare IRMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IRMDYou | $1B | 52.4 | 39.3 | 68.2 | 76.7% | 31.2% | 24.8% | 50.2% | — |
 LNTH | $7B | 31.1 | 17.2 | 19.5 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 PRCT | $1B | -12.2 | — | — | 63.7% | -33.7% | -24.9% | -55.7% | — |
 ANGO | $515M | -14.9 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 NVCR | $2B | -11.2 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 GEHC | $28B | 13.3 | 9.9 | 18.3 | 40.0% | 13.4% | 21.6% | 13.3% | 3.0 |
 STE | $20B | 25.3 | 19.2 | 20.2 | 44.2% | 18.6% | 11.4% | 9.5% | 1.8 |
 MMSI | $4B | 31.2 | 13.8 | 18.4 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 INVA | $2B | 6.9 | 6.8 | 8.5 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ATEC | $1B | -8.9 | 4030.4 | 466.2 | 69.6% | -10.7% | -630.7% | -12.6% | 1425.2 |
 SYK | $117B | 36.3 | 21.0 | 27.2 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
IRMD — Frequently Asked Questions
Quick answers to the most common questions about buying IRMD stock.
What is IRadimed Corporation's P/E ratio?
IRadimed Corporation's current P/E ratio is 52.4x. The historical average is 42.4x. This places it at the 70th percentile of its historical range.
What is IRadimed Corporation's EV/EBITDA?
IRadimed Corporation's current EV/EBITDA is 39.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 36.1x.
What is IRadimed Corporation's ROE?
IRadimed Corporation's return on equity (ROE) is 24.8%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 20.5%.
Is IRMD stock overvalued?
Based on historical data, IRadimed Corporation is trading at a P/E of 52.4x. This is at the 70th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is IRadimed Corporation's dividend yield?
IRadimed Corporation's current dividend yield is 1.28% with a payout ratio of 66.9%.
What are IRadimed Corporation's profit margins?
IRadimed Corporation has 76.7% gross margin and 31.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.